Cost-Effectiveness of Aspirin Use Among Persons With Newly Diagnosed Type 2 Diabetes

  1. Thomas J. Hoerger, PHD2
  1. 1Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia;
  2. 2Research Triangle Institute, Research Triangle Park, North Carolina.
  1. Corresponding author: Rui Li, rli2{at}


OBJECTIVE To assess the long-term cost-effectiveness of aspirin use among adults aged ≥40 years with newly diagnosed type 2 diabetes.

RESEARCH DESIGN AND METHODS We used a validated cost-effectiveness model of type 2 diabetes to assess the lifetime health and cost consequences of use or nonuse of aspirin. The model simulates the progression of diabetes and accompanying complications for a cohort of subjects with type 2 diabetes. The model predicts the outcomes of type 2 diabetes along five disease paths (nephropathy, neuropathy, retinopathy, coronary heart disease, and stroke) from the time of diagnosis until age 94 years or until death.

RESULTS Over a lifetime, aspirin users gained 0.31 life-years (LY) or 0.19 quality-adjusted LYs (QALYs) over nonaspirin users, at an incremental cost of $1,700; the incremental cost-effectiveness ratio (ICER) of aspirin use was $5,428 per LY gained or $8,801 per QALY gained. In probabilistic sensitivity analyses, the ICER was <$30,000 per QALY in all of 2,000 realizations in two scenarios.

CONCLUSIONS Regular use of aspirin among people with newly diagnosed diabetes is cost-effective.


  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Received October 12, 2009.
  • Accepted March 8, 2010.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See for details.

| Table of Contents

This Article

  1. Diabetes Care vol. 33 no. 6 1193-1199
  1. All Versions of this Article:
    1. dc09-1888v1
    2. 33/6/1193 most recent